×
Potential therapeutic options for COVID-19: an update on current evidence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755901
European Journal of Medical Research; Niknam Z, Jafari A et. al.

Jan 15th, 2022 - SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19 pandemic and is a major public health concern nowadays. The rapid and global spread of this coronavirus leads to an increase in hospitalizations and thousands of deaths in many countries. To date, great efforts have been made worldwide for the efficient management of this crisis, but there is still no effective and speci...

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654464
Drug Resistance Updates : Reviews and Commentaries in Ant... Drożdżal S, Rosik J et. al.

Jan 8th, 2022 - The COVID-19 pandemic is one of the greatest threats to human health in the 21st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic ag...

Cilta-cel Elicits Early, Deep Responses in Heavily Pretreated, Lenalidomide-Refractory Myeloma
https://www.onclive.com/view/cilta-cel-elicits-early-deep-responses-in-heavily-pretreated-lenalidomide-refractory-myeloma

Jan 4th, 2022 - A single infusion of ciltacabtagene autoleucel (cilta-cel) produced an overall response rate (ORR) of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide (Revlimid), according to updated data from cohort A of the phase 2 CARTITUDE-2 trial (NCT04133636) presented during the 2021 ASH Annual Meeting and Exposition.1 ...

Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of th...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717699
International Journal of Surgery (London, England); Dhawan M, Priyanka et. al.

Jan 3rd, 2022 - Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in a catastrophic pandemic and severely impacted people's livelihoods worldwide. In addition, the emergence of SARS-CoV-2 variants has posed a severe threat to humankind. Due to the dearth of therapeutic options during the commencement of the pandemic, convalescent plasma ther...

A hybrid soluble gp130/spike-nanobody fusion protein simultaneously blocks IL-6 trans-s...
https://doi.org/10.1128/JVI.01622-21
Journal of Virology; Ettich J, Werner J et. al.

Dec 23rd, 2021 - SARS-CoV2 infection can induce mild to life threatening symptoms. Especially individuals over 60 years of age or with underlying co-morbidities including heart or lung disease, and diabetes or immune compromised patients are at higher risk. Fatal multi-organ damage in COVID19 patients can be attributed to Interleukin (IL-)6 dominated cytokine storm. Consequently, IL-6R monoclonal antibody treat...

Recent Evidence and Possible Therapy against COVID-19-Mediated Hepatic Dysfunction.
https://doi.org/10.1615/JEnvironPatholToxicolOncol.2021039357
Journal of Environmental Pathology, Toxicology and Oncolo... Ali N

Dec 23rd, 2021 - Over the years, a novel RNA coronavirus has emerged with mutational episodes. This virus was confirmed to cause severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus infectious disease-2019 (COVID-19). This particular emphasis has raised the risk signal at the global level. Hepatic injury has been known to be a major impairment with varying factors. In recent years, the m...

Commentary: Morphoproteomics and Data Mining of the Medical Literature Define the Patho...
https://www.ncbi.nlm.nih.gov/pubmed/34921044
Annals of Clinical and Laboratory Science; Brown RE

Dec 19th, 2021 - Due to the resurgence of COVID-19, understanding the biology of SARS-CoV-2 is an opportunity to develop adjuvant therapies that could target its pathobiology and lessen the severity of the COVID-19 infection so that our patients could survive. This commentary serves to accomplish this by using published morphoproteomic findings with data mining of the medical literature to define the pathobiolo...

Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
https://doi.org/10.1183/16000617.0194-2021
European Respiratory Review : an Official Journal of the ... Mylvaganam RJ, Bailey JI et. al.

Dec 17th, 2021 - Acute manifestations of SARS-CoV-2 infection continue to impact the lives of many across the world. Post-acute sequelae of coronavirus disease 2019 (COVID-19) may affect 10-30% of survivors of COVID-19, and post-acute sequelae of COVID-19 (PASC)-pulmonary fibrosis is a long-term outcome associated with major morbidity. Data from prior coronavirus outbreaks (severe acute respiratory syndrome and...

Treatments for COVID-19: Lessons from 2020 and new therapeutic options.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598952
Current Opinion in Pharmacology; Salasc F, Lahlali T et. al.

Dec 17th, 2021 - To face the COVID-19 pandemic, prophylactic vaccines have been developed in record time, but vaccine coverage is still limited, accessibility is not equitable worldwide, and the vaccines are not fully effective against emerging variants. Therefore, therapeutic treatments are urgently needed to control the pandemic and treat vulnerable populations, but despite all efforts made, options remain sc...

COVID-19 related olfactory dysfunction.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711304
Current Opinion in Otolaryngology & Head and Neck Surgery; Karamali K, Elliott M et. al.

Dec 11th, 2021 - This article reviews the literature on COVID-19 related anosmia, focusing on the epidemiology, pathophysiology recovery rates, current available treatment options, and research regarding novel treatments. Loss of sense of smell is one of the most prevalent symptoms reported by patients after COVID-19 infection. Even though there is a high self-reported recovery rate, recent studies have demonst...

Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 seve...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635865
BMJ Open; Lovre D, Bateman K et. al.

Dec 2nd, 2021 - As of November 2021, COVID-19 has killed more than 5 million people globally, including over 750 000 in the USA. Apart from corticosteroids, most available therapeutic options are at best marginally efficient in reducing disease severity and are extremely expensive. The systematic investigation of clinically approved drugs is a priority to determine what does mitigate disease severity. Oestradi...

Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COV...
https://doi.org/10.1097/FTD.0000000000000945
Therapeutic Drug Monitoring; Wieland E

Nov 30th, 2021 - The COVID-19 pandemic has posed a great challenge to the medical community because little is known about its clinical course, therapeutic options, and laboratory monitoring tools for diagnosis, prognosis, and surveillance. This review focuses on immune biomarkers that can be measured in peripheral blood in a clinical laboratory under routine conditions to monitor the innate immune system respon...

Advances in Diagnostics and Therapeutics Propel Interventional Pulmonology Forward
https://www.onclive.com/view/advances-in-diagnostics-and-therapeutics-propel-interventional-pulmonology-forward

Nov 23rd, 2021 - Significant developments with advanced diagnostics and therapeutics have pushed the field of interventional pulmonology into a period of rapid change, said Nathaniel Ivanick, MD, FCCP, who added that cutting-edge technologies such as robotic navigational bronchoscopy have enabled the identification and treatment of lung nodules to become more accurate, stable, and effective than conventional ap...

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVI...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648031
Emerging Microbes & Infections; Camelo S, Latil M et. al.

Nov 17th, 2021 - Since December 2019, coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has changed our lives. Elderly and those with comorbidities represent the vast majority of patients hospitalized with severe COVID-19 symptoms, including acute respiratory disease syndrome and cardiac dysfunction. Despite a huge effort of the scientifi...

Sacubitril/Valsartan No Better Than Valsartan Alone in Advanced HF
https://www.medscape.com/viewarticle/962793

Nov 15th, 2021 - NEW YORK (Reuters Health) - In patients with chronic advanced heart failure (HF) with a reduced ejection fraction enrolled in the LIFE trial, sacubitril/valsartan and valsartan alone similarly lowered N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, but the combination treatment was less well tolerated. "Given the striking improvements that were observed in less severe HF in PARADIG...

COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563344
International Immunopharmacology; Thapa K, Verma N et. al.

Nov 13th, 2021 - The novel Coronavirus disease 2019 (COVID-19) has caused great distress worldwide. Acute respiratory distress syndrome (ARDS) is well familiar but when it happens as part of COVID-19 it has discrete features which are unmanageable. Numerous pharmacological treatments have been evaluated in clinical trials to control the clinical effects of CARDS, but there is no assurance of their effectiveness...

A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570825
Complementary Therapies in Medicine; Barber MS, Barrett R et. al.

Nov 9th, 2021 - The coronavirus disease 2019 (COVID-19) pandemic has led to significant morbidity and mortality. Although COVID-19 vaccination is available, therapeutic options are still needed. The goal of the present manuscript is to report on a treatment strategy used in a naturopathic medical practice for mild and moderate COVID-19. A retrospective chart review was conducted of 30 consecutive patients diag...

Acute central and peripheral nervous system injury associated with coronavirus disease ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577290
Current Opinion in Pediatrics; Simon DW, Schober ME

Oct 21st, 2021 - Acute central and peripheral nervous system injury may occur in association with coronavirus disease 2019 (COVID-19) caused by infection with the severe acute respiratory syndrome coronavirus 2 virus. This review will assist readers to recognize neurologic manifestations associated with COVID-19 including common and life-threatening symptoms and diagnostic testing. We will also review current r...

Current treatment strategies for COVID‑19 (Review).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548951
Molecular Medicine Reports; Han F, Liu Y et. al.

Oct 20th, 2021 - The spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) emerged suddenly at the end of 2019 and the disease came to be known as coronavirus disease 2019 (COVID‑19). To date, there is no specific therapy established to treat COVID‑19. Identifying effective treatments is urgently required to treat patients and stop the transmission of SARS‑CoV‑2 in humans. For the pre...

Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVI...
https://doi.org/10.5603/CJ.a2021.0123
Cardiology Journal; Surma S, Basiak M et. al.

Oct 14th, 2021 - Colchicine is an effective anti-inflammatory agent used to treat gout, coronary artery disease, viral pericarditis, and familial Mediterranean fever. It has been found to act by preventing the polymerization of the protein called tubulin, thus inhibiting inflammasome activation, proinflammatory chemokines, and cellular adhesion molecules. Accumulating evidence suggests that some patients with c...